skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Concepts for the Design of a Diagnostic Device to Detect Malignancies in Human Tissues Final Report CRADA No. TSB-2023-00

Abstract

BioLuminate, Inc. planned to develop, produce and market a revolutionary diagnostic device for early breast cancer diagnosis. The device was originally invented by NASA; and exclusively licensed to BioLuminate for commercialization. At the time of the CRADA, eighty-five percent (85%) of all biopsies in the United States were found negative each year. The number of biopsies cost the health care system $23 billio n annually. A multi-sensor probe would allow surgeons to improve breast cancer scre ening and significantly reduce the number of biopsies. BioLuminate was developing an in-vivo system for the detection of cancer using a multi-sensor needle/probe. The first system would be developed for the detection of breast cancer. LLNL, in collaboration with BioLuminate worked toward a detailed concept specification for the prototype multi-sensor needle/probe suitable for breast cancer analysis. BioLuminate in collaboration with LLNL, worked to develop a new version of the needle probe that would be the same size as needles commonly used to draw blood.

Authors:
 [1];  [1];  [1]
  1. Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
Publication Date:
Research Org.:
Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1406451
Report Number(s):
LLNL-TR-740389
DOE Contract Number:
AC52-07NA27344
Resource Type:
Technical Report
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES

Citation Formats

DaSilva, L., Marion, J., and Chase, C. Concepts for the Design of a Diagnostic Device to Detect Malignancies in Human Tissues Final Report CRADA No. TSB-2023-00. United States: N. p., 2017. Web. doi:10.2172/1406451.
DaSilva, L., Marion, J., & Chase, C. Concepts for the Design of a Diagnostic Device to Detect Malignancies in Human Tissues Final Report CRADA No. TSB-2023-00. United States. doi:10.2172/1406451.
DaSilva, L., Marion, J., and Chase, C. Thu . "Concepts for the Design of a Diagnostic Device to Detect Malignancies in Human Tissues Final Report CRADA No. TSB-2023-00". United States. doi:10.2172/1406451. https://www.osti.gov/servlets/purl/1406451.
@article{osti_1406451,
title = {Concepts for the Design of a Diagnostic Device to Detect Malignancies in Human Tissues Final Report CRADA No. TSB-2023-00},
author = {DaSilva, L. and Marion, J. and Chase, C.},
abstractNote = {BioLuminate, Inc. planned to develop, produce and market a revolutionary diagnostic device for early breast cancer diagnosis. The device was originally invented by NASA; and exclusively licensed to BioLuminate for commercialization. At the time of the CRADA, eighty-five percent (85%) of all biopsies in the United States were found negative each year. The number of biopsies cost the health care system $23 billio n annually. A multi-sensor probe would allow surgeons to improve breast cancer scre ening and significantly reduce the number of biopsies. BioLuminate was developing an in-vivo system for the detection of cancer using a multi-sensor needle/probe. The first system would be developed for the detection of breast cancer. LLNL, in collaboration with BioLuminate worked toward a detailed concept specification for the prototype multi-sensor needle/probe suitable for breast cancer analysis. BioLuminate in collaboration with LLNL, worked to develop a new version of the needle probe that would be the same size as needles commonly used to draw blood.},
doi = {10.2172/1406451},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Thu Oct 19 00:00:00 EDT 2017},
month = {Thu Oct 19 00:00:00 EDT 2017}
}

Technical Report:

Save / Share: